Calliditas Therapeutics IPO Presentation Deck

Proteinuria surrogate endpoint evaluation Trial Level Analysis, published by Inker et al, 2016 Establish correlation between proteinuria and risk for ESRD Treatment effect on clinical outcome 2.72 calliditas 0.65 1.00 0.37- 0.22 0.14 0.08 0.05 0.30 A OAD SINA VA 40 40 V v 0.55 1 Treatment effect on proteinuria Locatelli MINIF R²=0.90 (0.47-1.0) Slope = 2.15 (0.10 -4.23) P2B = 29% reduction in proteinuria → 65% reduction in risk of ESRD → 32% upper 97.5% confidence limit *Clinical Outcome (ESRD) doubling of serum creatinine, need for dialysis, kidney transplant or death due to kidney disease ** 16 mg NEFECON dose group vs Placebo dose group June 2020 34

View entire presentation